SCHEMBL21244040

SCHEMBL21244040

Cc1ccccc1S(=O)(=O)Nc1ccccc1N1CCN(c2ccc(Cl)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPT P10636 6/20 0.45
HTT P42858 3/20 0.45
KDM4E B2RXH2 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MCL1 Q07820 1/20 0.45
CCR2 P41597 2/20 0.44
MCOLN3 Q8TDD5 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 1/20 0.44
LMNA P02545 3/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244030 0.85 MAPT (0.55) ALDH1A1MAPTHTTKDM4EMCOLN3
SCHEMBL21244042 0.80 ALDH1A1 (0.52) ALDH1A1MAPTHTTKDM4EMCOLN3
SCHEMBL21244051 0.80 MCOLN3 (0.55) ALDH1A1MAPTMCOLN3L3MBTL1PKM
SCHEMBL23355033 0.80 ALDH1A1 (0.52) ALDH1A1MAPTHTTCCR2MCOLN3
SCHEMBL21244038 0.79 ALDH1A1 (0.54) ALDH1A1MAPTHTTKDM4ECYP2D6
SCHEMBL21244034 0.79 L3MBTL1 (0.53) ALDH1A1MAPTHTTMCOLN3L3MBTL1
SCHEMBL29978716 0.79 MCOLN3 (0.60) ALDH1A1MAPTKDM4ECYP3A4MCOLN3
SCHEMBL23043650 0.79 MCOLN3 (0.60) ALDH1A1MAPTKDM4ECYP3A4MCOLN3
SCHEMBL21244031 0.78 MCOLN3 (0.52) ALDH1A1MAPTKDM4ECCR2MCOLN3
SCHEMBL29512713 0.78 ALDH1A1 (0.52) ALDH1A1MAPTHTTKDM4ECCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US claimed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US claimed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851084-B2 Piperazine derivatives as TRPML modulators TRPM5, TRPM2, TRPM4 ALDH1A1 2820/4885MAPT 577/4885HTT 531/4885
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS TRPM5, TRPM2, TRPM4 ALDH1A1 2820/4885MAPT 577/4885HTT 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.